,,ii  #aafth ,,congress  #b;d ,session  
,s4 #diei  ,,in ,,the ,,senate ,,of     
,,the ,,united ,,states  ,december #c1  
#bjbj,mr4 ,braun introduced the         
following bill2 which was read twice and
 referred to the ,committee on ,health1 
,education1 ,labor1 and ,pensions  ,a   
,,bill  ,to increase transparency and   
access to group health plan and health  
issuer reporting1 and for other         
purposes4  #a4 ,reporting on pharmacy   
benefits and drug costs  7a7 ,,psha     
,subpart ,,ii of part ,a of title       
,,xxvii of the ,public ,health ,service 
,act 7#db ,u4,s4,c4 #cjj;gg-#aa et seq47
 is amended by adding at the end the    
following3  #bgbi;,a4 ,reporting on     
pharmacy benefits and drug costs  7a7   
,in general ,not later than #a year     
after the date of enactment of this     
section1 and not later than ,march #a of
 each year thereafter1 a group health   
plan or health insurance issuer offering
 group or individual health insurance   
coverage 7except for a church plan7     

shall submit to the ,secretary1 the     
,secretary of ,labor1 and the ,secretary
 of the ,treasury the following         
information with respect to the health  
plan or coverage in the previous plan   
year3 7#a7 ,the beginning and end dates 
of the plan year4  7#b7 ,the number of  
enrollees4  7#c7 ,each ,state in which  
the plan or coverage is offered4  7#d7  
,the #ej brand prescription drugs most  
frequently dispensed by pharmacies for  
claims paid by the plan or coverage1 and
 the total number of paid claims for    
each such drug4  7#e7 ,the #ej most     
costly prescription drugs with respect  
to the plan or coverage by total annual 
spending1 and the annual amount spent by
 the plan or coverage for each such     
drug4  7#f7 ,the #ej prescription drugs 
with the greatest increase in plan      
expenditures over the plan year         
preceding the plan year that is the     
subject of the report1 and1 for each    
such drug1 the change in amounts        
expended by the plan or coverage in each

 such plan year4  7#g7 ,total spending  
on health care services by such group   
health plan or health insurance         
coverage1 broken down by-- 7,a7 the type
 of costs1 including-- 7i7 hospital     
costs2  7ii7 health care provider and   
clinical service costs1 for primary care
 and specialty care separately2  7iii7  
costs for prescription drugs2 and  7iv7 
other medical costs1 including wellness 
services2 and  7,b7 spending on         
prescription drugs by-- 7i7 the health  
plan or coverage2 and  7ii7 the         
enrollees4  7#h7 ,the average monthly   
premium-- 7,a7 paid by employers on     
behalf of enrollees1 as applicable2 and 
7,b7 paid by enrollees4  7#i7 ,any      
impact on premiums by rebates1 fees1 and
 any other remuneration paid by drug    
manufacturers to the plan or coverage or
 its administrators or service          
providers1 with respect to prescription 
drugs prescribed to enrollees in the    
plan or coverage1 including-- 7,a7 the  
amounts so paid for each therapeutic    

class of drugs2 and  7,b7 the amounts so
 paid for each of the #be drugs that    
yielded the highest amount of rebates   
and other remuneration under the plan or
 coverage from drug manufacturers during
 the plan year4  7#aj7 ,any reduction in
 premiums and out-of-pocket costs       
associated with rebates1 fees1 or other 
remuneration described in paragraph     
7#i74  7b7 ,report ,not later than #ah  
months after the date on which the first
 report is required under subsection 7a7
 and biannually thereafter1 the         
,secretary1 acting through the          
,assistant ,secretary of ,planning and  
,evaluation and in coordination with the
 ,inspector ,general of the ,department 
of ,health and ,human ,services1 shall  
make available on the internet website  
of the ,department of ,health and ,human
 ,services a report on prescription drug
 reimbursements under group health plans
 and group and individual health        
insurance coverage1 prescription drug   
pricing trends1 and the role of         

prescription drug costs in contributing 
to premium increases or decreases under 
such plans or coverage1 aggregated in   
such a way as no drug or plan specific  
information will be made public4  7c7   
,privacy protections ,no confidential or
 trade secret information submitted to  
the ,secretary under subsection 7a7     
shall be included in the report under   
subsection 7b74  4  7b7 ,,erisa ,subpart
 ,b of part #g of subtitle ,b of title  
,i of the ,employee ,retirement ,income 
,security ,act of #aigd 7#bi ,u4,s4,c4  
#aahe et seq47 is amended by adding at  
the end the following3  #gaf4 ,reporting
 on pharmacy benefits and drug costs    
7a7 ,in general ,not later than #a year 
after the date of enactment of this     
section1 and not later than ,march #a of
 each year thereafter1 a group health   
plan 7or health insurance coverage      
offered in connection with such a plan7 
shall submit to the ,secretary1 the     
,secretary of ,health and ,human        
,services1 and the ,secretary of the    

,treasury the following information with
 respect to the health plan or coverage 
in the previous plan year3 7#a7 ,the    
beginning and end dates of the plan     
year4  7#b7 ,the number of participants 
and beneficiaries4  7#c7 ,each ,state in
 which the plan or coverage is offered4 
7#d7 ,the #ej brand prescription drugs  
most frequently dispensed by pharmacies 
for claims paid by the plan or coverage1
 and the total number of paid claims for
 each such drug4  7#e7 ,the #ej most    
costly prescription drugs with respect  
to the plan or coverage by total annual 
spending1 and the annual amount spent by
 the plan or coverage for each such     
drug4  7#f7 ,the #ej prescription drugs 
with the greatest increase in plan      
expenditures over the plan year         
preceding the plan year that is the     
subject of the report1 and1 for each    
such drug1 the change in amounts        
expended by the plan or coverage in each
 such plan year4  7#g7 ,total spending  
on health care services by such group   

health plan or health insurance         
coverage1 broken down by-- 7,a7 the type
 of costs1 including-- 7i7 hospital     
costs2  7ii7 health care provider and   
clinical service costs1 for primary care
 and specialty care separately2  7iii7  
costs for prescription drugs2 and  7iv7 
other medical costs1 including wellness 
services2 and  7,b7 spending on         
prescription drugs by-- 7i7 the health  
plan or coverage2 and  7ii7 the         
participants and beneficiaries4  7#h7   
,the average monthly premium-- 7,a7 paid
 by employers on behalf of participants 
and beneficiaries1 as applicable2 and   
7,b7 paid by participants and           
beneficiaries4  7#i7 ,any impact on     
premiums by rebates1 fees1 and any other
 remuneration paid by drug manufacturers
 to the plan or coverage or its         
administrators or service providers1    
with respect to prescription drugs      
prescribed to participants and          
beneficiaries in the plan or coverage1  
including-- 7,a7 the amounts so paid for

 each therapeutic class of drugs2 and   
7,b7 the amounts so paid for each of the
 #be drugs that yielded the highest     
amount of rebates and other remuneration
 under the plan or coverage from drug   
manufacturers during the plan year4     
7#aj7 ,any reduction in premiums and    
out-of-pocket costs associated with     
rebates1 fees1 or other remuneration    
described in paragraph 7#i74  7b7       
,report ,not later than #ah months after
 the date on which the first report is  
required under subsection 7a7 and       
biannually thereafter1 the ,secretary1  
acting in coordination with the         
,inspector ,general of the ,department  
of ,labor1 shall make available on the  
internet website of the ,department of  
,labor a report on prescription drug    
reimbursements under group health plans 
7or health insurance coverage offered in
 connection with such a plan71          
prescription drug pricing trends1 and   
the role of prescription drug costs in  
contributing to premium increases or    

decreases under such plans or coverage1 
aggregated in such a way as no drug or  
plan specific information will be made  
public4  7c7 ,privacy protections ,no   
confidential or trade secret information
 submitted to the ,secretary under      
subsection 7a7 shall be included in the 
report under subsection 7b74  4  7c7    
,,irc ,subchapter ,b of chapter #ajj of 
the ,internal ,revenue ,code of #aihf is
 amended by adding at the end the       
following3  #ihaf4 ,reporting on        
pharmacy benefits and drug costs  7a7   
,in general ,not later than #a year     
after the date of enactment of this     
section1 and not later than ,march #a of
 each year thereafter1 a group health   
plan shall submit to the ,secretary1 the
 ,secretary of ,health and ,human       
,services1 and the ,secretary of ,labor 
the following information with respect  
to the health plan in the previous plan 
year3 7#a7 ,the beginning and end dates 
of the plan year4  7#b7 ,the number of  
participants and beneficiaries4  7#c7   

,each ,state in which the plan is       
offered4  7#d7 ,the #ej brand           
prescription drugs most frequently      
dispensed by pharmacies for claims paid 
by the plan1 and the total number of    
paid claims for each such drug4  7#e7   
,the #ej most costly prescription drugs 
with respect to the plan by total annual
 spending1 and the annual amount spent  
by the plan for each such drug4  7#f7   
,the #ej prescription drugs with the    
greatest increase in plan expenditures  
over the plan year preceding the plan   
year that is the subject of the report1 
and1 for each such drug1 the change in  
amounts expended by the plan in each    
such plan year4  7#g7 ,total spending on
 health care services by such group     
health plan1 broken down by-- 7,a7 the  
type of costs1 including-- 7i7 hospital 
costs2  7ii7 health care provider and   
clinical service costs1 for primary care
 and specialty care separately2  7iii7  
costs for prescription drugs2 and  7iv7 
other medical costs1 including wellness 

services2 and  7,b7 spending on         
prescription drugs by-- 7i7 the health  
plan2 and  7ii7 the participants and    
beneficiaries4  7#h7 ,the average       
monthly premium-- 7,a7 paid by employers
 on behalf of participants and          
beneficiaries1 as applicable2 and  7,b7 
paid by participants and beneficiaries4 
7#i7 ,any impact on premiums by rebates1
 fees1 and any other remuneration paid  
by drug manufacturers to the plan or its
 administrators or service providers1   
with respect to prescription drugs      
prescribed to participants or           
beneficiaries in the plan1 including--  
7,a7 the amounts so paid for each       
therapeutic class of drugs2 and  7,b7   
the amounts so paid for each of the #be 
drugs that yielded the highest amount of
 rebates and other remuneration under   
the plan from drug manufacturers during 
the plan year4  7#aj7 ,any reduction in 
premiums and out-of-pocket costs        
associated with rebates1 fees1 or other 
remuneration described in paragraph     

7#i74  7b7 ,report ,not later than #ah  
months after the date on which the first
 report is required under subsection 7a7
 and biannually thereafter1 the         
,secretary1 acting in coordination with 
the ,inspector ,general of the          
,department of the ,treasury1 shall make
 available on the internet website of   
the ,department of the ,treasury a      
report on prescription drug             
reimbursements under group health plans1
 prescription drug pricing trends1 and  
the role of prescription drug costs in  
contributing to premium increases or    
decreases under such plans1 aggregated  
in such a way as no drug or plan        
specific information will be made       
public4  7c7 ,privacy protections ,no   
confidential or trade secret information
 submitted to the ,secretary under      
subsection 7a7 shall be included in the 
report under subsection 7b74  4  7d7    
,clerical amendments  7#a7 ,,erisa ,the 
table of contents in section #a of the  
,employee ,retirement ,income ,security 

,act of #aigd 7#bi ,u4,s4,c4 #ajja et   
seq47 is amended by inserting after the 
item relating to section #gad the       
following new items3  ,sec4 #gae4       
,additional market reforms4,sec4 #gaf4  
,reporting on pharmacy benefits and drug
 costs4  4  7#b7 ,,irc ,the table of    
sections for subchapter ,b of chapter   
#ajj of the ,internal ,revenue ,code of 
#aihf is amended by adding at the end   
the following new item3  ,sec4 #ihaf4   
,reporting on pharmacy benefits and drug
 costs4  4